Allogene Therapeutics ALLO Occupancy and Related Charges
Occupancy and Related Charges at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseExpense.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's occupancy and related charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's occupancy and related charges?
- Allogene Therapeutics (ALLO) reported occupancy and related charges of $1.07M in Q1 2026.
- How has Allogene Therapeutics's occupancy and related charges changed year-over-year?
- Allogene Therapeutics's occupancy and related charges decreased by 5.4% year-over-year, from $1.13M to $1.07M.
- What is the long-term trend for Allogene Therapeutics's occupancy and related charges?
- Over 4 years (2021 to 2025), Allogene Therapeutics's occupancy and related charges has grown at a 13.5% compound annual growth rate (CAGR), from $2.62M to $4.36M.
- What does occupancy and related charges mean?
- This captures the periodic expense recognized for the use of leased assets, such as office space or laboratory facilities, under operating lease agreements. It represents the portion of lease payments that is treated as an operating cost rather than a financing activity. Monitoring this helps assess the company's fixed overhead commitments and facility footprint.